Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations.

With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.

Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.

Bausch + Lomb's stock soars 18% on report company is considering selling itself

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Bausch Health (BHC) is a Strong Momentum Stock

LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to provide a safe and effective treatment.1 "The approval of CABTREO shows the continuing commitment of Bausch Health to bring innovative dermatology treatments to Canadians," said Amy Cairns, Vice-President, Commercial and General Manager, Canada, Bausch Health. "We are proud to offer this first triple-combination topical acne treatment to millions of Canadians who suffer from acne each year.

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.

Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

On Thursday, Bausch Health Companies BHC reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28.

Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock

Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.

Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales

Bausch Health Companies (NYSE:BHC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Interim Chief Financial Officer Garen Sarafian - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Mike Nedelcovych - TD Cowen Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Michael Freeman - Raymond James Operator Greetings! Welcome to the Bausch Health Second Quarter 2024 Earnings Call.

Bausch Health Companies (BHC) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.81 per share a year ago.

Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter. "We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy.

Bausch Health Announces Second Quarter 2024 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. “Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitment to innovation that defined our past and will dictate our future,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “That commitment was on full displ.

Bausch + Lomb Announces Second-Quarter 2024 Results

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

Rumors circulated on a pre-packaged bankruptcy filing, which Bausch Health Companies quickly refuted. Bausch Health stock previously plummeted after posting Q1 results. BHC's cash flow remains weak, with concerns over long-term debt and limited resources for growth.

2 Red Alerts On Bausch Health Companies

It was quite a day for shares of Bausch Health Cos. (BHC), which were cut nearly in half before recovering as it addressed a research firm's report saying it was mulling bankruptcy options.

Bausch Health Stock Swings Wildly as it Addresses Report It's Considering Bankruptcy

Specialty pharmaceutical and medical device firm Bausch Health (NYSE: BHC ) saw its shares tumble badly on Wednesday. Driving the negativity was a report by Reorg — billed as a global provider of credit intelligence, data and analytics for leveraged finance professionals — that the company was on the brink of bankruptcy.

BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy

Bausch Health said on Wednesday it was not considering a bankruptcy or insolvency proceeding of any kind.

Bausch Health denies report of bankruptcy filing

LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources. The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy or insolvency proceeding of any kind - it is not.

Bausch Health Responds to Market Rumors

Shares of Bausch Health Companies Inc. BHC, -21.60% have been halted for news, with the last trade at a 14-month low. The Canada-based drug and medical devices company's stock was down 21.6% when it was halted at 12:21 p.m.

Bausch Health's stock halted for news, after tumbling more than 20%

LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024.

Bausch Health Welcomes Two New Members to the Executive Leadership Team

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start.

Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich Pharmaceuticals, Inc. This lawsuit was filed in connection with the Notice of Paragraph IV Certification, dated May 10, 2024, received from Norwich advising that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to an Abbreviated New Drug Application (ANDA) requesting approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Bausch Health continues to defend challenges to its XIFAXAN® intellectual property.

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroenterology (GI) business, Salix Pharmaceuticals presented data from its Amiselimod clinical trials at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on May 19, 2024, in Washington, D.C.

News for Bausch Health Companies Inc Stock (BHC)